Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
Shares gained 21.6% over 21 trading days and broke above the prior $227.69 peak. Earnings and revenue exceeded expectations, guidance improved, and S&P 500 inclusion effective September 21 may create near-term index demand.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: ⢠Strong Margins ⢠Weaker Liquidity ⢠High Leverage ILMN remains profitable with strong margins, but weakening liquidity, lower recent cash generation, high debt, and elevated valuation warrant caution.
Price Behavior
Key Price Behavior Insights: ⢠Constructive rebound ⢠Lower-high pressure ⢠Key level watch Support Level: $200â$205; stronger at $188â$192 Resistance Level: $218â$222; major at $224â$228 ILMN's last-month rebound is constructive, but momentum remains mixed below $218â$228 resistance; hold $200 support and watch for a breakout above $228 or breakdown below $188.
Sentiment & News
Key News Insights: ⢠Raised Guidance ⢠S&P Inclusion ⢠Margin Pressure Illumina's earnings beat, raised guidance, analyst upgrades, and S&P 500 inclusion strengthen near-term momentum, but valuation concerns, margin risk, and slow historical growth remain key watchpoints.
AI Summary
ILMN is now a high-expectations execution story rather than a simple turnaround: maintain or add exposure only if mid-single-digit organic growth and free-cash-flow margins stabilize, as its premium valuation and leverage leave little room for margin erosion or weaker demand.
Description
Illumina, Inc. supplies sequencing and array-based instruments, consumables and related services for genetic and genomic analysis used across research and clinical environments, including applications in oncology, reproductive health and agriculture. Its clientele includes academic and government research centers, hospitals, pharmaceutical and biotechnology companies, diagnostic laboratories and consumer genomics firms, and it sells directly in major regions and through life-science distributors worldwide; the company was founded in 1998 and is based in San Diego, California.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Sep 16 | Sep 23 | ILMN | Illumina, Inc. | Shares gained 21.6% over 21 trading days and broke above the prior $227.69 peak. Earnings and revenue exceeded expectations, guidance improved, and S&P 500 inclusion effective September 21 may create near-term index demand. | Active | +0.0% |